Coronavirus rapid antigen test for early diagnosis

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)

Sensitive:
95 % sensitivity compared to PCR with a Ct value of < 29

Specific:
100 % specificity compared to PCR

Quality:
Developed and manufactured in Germany under ISO 13485

More information:

https://r-b.io/n6803_en

R-Biopharm • An der neuen Bergstraße 17, 64297 Darmstadt, Germany • E-mail: orders@r-biopharm.de • www.r-biopharm.com

Rapid test information
RIDA®QUICK SARS-CoV-2 Antigen

Art. No. N6803

Your advantages

Accurate:
Immunochromatographic detection of the SARS-CoV-2 nucleocapsid antigen, no cross-reactivity with common human coronaviruses

Reliable:
High analytical sensitivity of 237 TCID50/mL

Dependable:
An integrated control line shows the validity of the result

Fast and simple:
Test system including swab system, qualitative visual evaluation without equipment, results in only 20 minutes

RIDA®QUICK SARS-CoV-2 Antigen, Art. No. N6803

SARS-CoV-2 Antigen diagnostic test

Rapid antigen tests are a good option for early diagnosis in people with a high viral load, which occurs 1 to 3 days prior to the start of symptoms and in the early symptomatic phase (within 5 to 7 days).[1]

Regulatory measures can be introduced quickly through the use of SARS-CoV-2 antigen tests.[2] Because it is relatively common, the nucleocapsid protein is the recommended target for rapid antigen tests. The WHO recommends a sensitivity of ≥ 80 % and a specificity of ≥ 97 % compared to PCR.[1]

Clinical sensitivity compared to PCR			
PCR Ct value	<Ct28	<Ct29	<Ct30
Sensitivity	100 %	95 %	90 %

Clinical specificity compared to PCR	
Specificity	100 %

[1] Antigen-detection in the diagnosis of SARS-CoV-2 infection using rapid immunoassays. Interim guidance 11. September 2020. WHO Referenznummer: WHO/2019-nCoV/Antigen_Detection/2020.1

[2] European Centre for Disease Prevention and Control. COVID-19 testing strategies and objectives. 15. September 2020. ECDC: Stockholm; 2020.